Table 1.

Comparison of baseline clinical and demographic characteristics between the three treatment groups

Baseline Variable	Citalopram + Placebo (n=48)				Methylphenidate + Placebo (n=47)				Methylphenidate + Citalopram (n=48)
	Mean	SD	N	%	Mean	SD	N	%	Mean	SD	N	%	P value
Demographics
Age	70.1	7.1			70.0	7.1			68.9	7.6			.7
Women (%)			31	65.0			19	40.0			28	58.0	.05
Education	15.8	2.7			16.0	2.4			15.2	3.0			.3
Race (%)													.9
Caucasian			36	75.0			35	74.4			37	77.0
African American			5	10.5			5	10.6			5	10.4
Asian			1	2.0			2	4.4			3	6.3
Hispanic			6	12.5			5	10.6			3	6.3
Age at depression onset	42.7	23.5			40.4	25.1			45.6	22.3			.6
Number of episodes	3.8	3.8			4.0	5.4			3.3	2.9			.7
Chronic course >24 month (%)			41	85.0			37	78.1			37	78.1	.6
Duration of episode (month)	51.6	45.6			50.2	47.2			38.6	31.8			.3
Psychiatric Symptoms
HDRS-24*	18.3	2.3			19.8	3.6			18.7	2.9			.04
Montgomery Asberg	18.	3.1			18.2	4.1			17.5	3.4			.3
Depression Rating Scale	6
Apathy Evaluation Scale	31.3	8.6			31.0	10.6			30.0	10.1			.8
Hamilton Anxiety Scale	8.9	2.4			9.9	3.2			8.7	2.9			.07
Comorbid Medical Symptoms
Cumulative Illness	5.8	4.6			5.5	3.5			4.0	3.2			.04
Rating Scale-Geriatrics
Cerebrovascular Risk Factor	12.2	5.8			10.9	5.0			9.7	4.5			.06
Health-related quality of life
Short-Form Health Survey
Energy	30.9	18.8			33.3	20.0			31.3	20.3			.8
Wellbeing	44.2	17.6			47.3	15.6			45.6	17.2			.7
Role-Emotional	34.0	27.9			37.6	28.3			31.2	26.1			.5

Note: *HDRS-24- Hamilton Depression Rating Scale-24 Item

SD-standard deviation